OncoMed Pharmaceuticals — Merger or Acquisition (December 2018)
12 slides from OncoMed Pharmaceuticals's merger presentation, Dec 6, 2018
Slide 1: Combination of Mereo BioPharma and OncoMed Pharmaceuticals
5 December 2018 Combination of Mereo BioPharma and OncoMed Pharmaceuticals Exhibit 99.2
Slide 2: Disclaimer
Disclaimer Mereo BioPharma Group plc No Offer or Solicitation This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote in any jur
Slide 3: Forward Looking Statements
FORWARD LOOKING STATEMENTS Mereo BioPharma Group plc Forward-Looking Statements This communication contains “forward-looking statements”. All statements other than statements of historical fact contained in this report are forward-looking statements within the meaning of Section 27A of the United St
Slide 4: Key Transaction Terms
Key Transaction TERMS 40.1cm wide 20 pre-set page layouts for use under “Home” / Layout 21.2cm high Upfront Stock Consideration Issuance of new Mereo shares (in the form of newly registered ADRs) to OncoMed shareholders Ownership split on completion 75% Mereo / 25% OncoMed shareholders(1) Considerat
Slide 5: Overview of OncoMed
Overview of Oncomed OncoMed Overview Clinical stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics Headquartered in Redwood City, California Currently has three therapeutic candidates in clinical development (Phase 1/1b) Extensive experience in adminis
Slide 6: Strategic Rationale for the Combination
Strategic Rationale for the Combination 40.1cm wide 20 pre-set page layouts for use under “Home” / Layout 21.2cm high Three phase 2 readouts in core orphan products in 2019 (Mereo’s BPS-804 and MPH-966) Potential partnerships of Mereo’s BCT-197 and BGS-649 programs Potential partnership of OncoMed’s
Slide 7: Management & Governance
Dr. Peter Fellner Chairman Richard Jones Executive Director CFO Management & Governance John Richard Head of Corporate Development Richard Jones Chief Financial Officer Dr. Denise Scots-Knight Chief Executive Officer Wills Hughes-Wilson Head of Patient Access & Commercial Planning Charles Sermon Gen
Slide 8: Overview of Mereo – Current Product Pipeline
Product Candidate Indication Phase 1 Phase 2a Phase 2b Last Milestone Next Anticipated Milestones BPS-804 (setrusumab) Osteogenesis Imperfecta Phase 2b initiated MPH-966 (alvelestat) Severe Alpha-1 Antitrypsin Deficiency Positive Phase2 data in bronchiectasis Phase 2 trial top-line data in severe AA
Slide 9: Overview of Mereo – Upcoming key milestones
2018 2019 2020 2021 BPS-804 MPH-966 BGS-649 BCT-197 Additional Products Overview of Mereo – Upcoming key milestones Pediatric Pivotal 12 month fracture Phase II Option : Commercial partnering Commercial partnering New product opportunities Adult HRPqCT data 6 m 12 m Extension Phase II POC Study Phas
Slide 10: Corporate and Commercial Strategy
corporate and commercial strategy Bone/ Musculoskeletal Respiratory Endocrine BPS-804 Setrusumab BGS-649 * Leflutrozole MPH-966 Alvelestat BCT-197 * Acumapimod * Plan to partner for development and commercialization Potential new products Potential new products Key in House Expertise Development Reg
Slide 11: Next Steps
Next Steps 40.1cm wide 20 pre-set page layouts for use under “Home” / Layout 21.2cm high Filing with the SEC of a Registration Statement on Form F-4 for Mereo Proxy statement of OncoMed (to be included in Mereo Form F-4) OncoMed shareholder meeting Targeting completion in H1 2019
Slide 12: Mereo BioPharma Group plc
Mereo BioPharma Group plc One Cavendish Place London, W1G 0QF UK +44 (0)333 0237 300
OncoMed Pharmaceuticals — Merger or Acquisition (December 2018) on 6ix